following a resubmission considered under the end of life / orphan medicine process:
paclitaxel albumin (Abraxane®) is accepted for use within NHS Scotland.
Indication under review: in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
In a randomised, phase III, open-label study paclitaxel albumin plus gemcitabine treatment improved median overall survival by 1.8 months compared with gemcitabine alone.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice181KB (PDF)
- Medicine name:
- paclitaxel albumin (Abraxane)
- SMC ID:
- In combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
- Pharmaceutical company
- Celgene Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published
- 09 February 2015